



Press Statement:
April 20, 2017

Media Contact:
Rachel Hooper
212.733.2105
Rachel.Hooper@Pfizer.com

**Updated Pfizer Statement On The Misuse Of Our Products In Lethal
Injections For Capital Punishment**

We support McKesson's efforts to seek the return of products intended for misuse from the state of Arkansas, which Pfizer has already twice requested.

Pfizer makes its products to enhance and save the lives of the patients we serve. We strongly object to the use of any of our products in the lethal injection process for capital punishment. We are committed to ensuring that our products remain available and accessible to the medical professionals and patients who rely upon them every day. We have implemented a comprehensive strategy and enhanced restricted distribution protocols for a select group of products to help combat their unauthorized use for capital punishment.

Our distribution restriction limits the sale of eleven products to a select group of wholesalers, distributors and direct purchasers, under the condition they will not resell those products to correctional facilities for use in lethal injection. Government purchasing entities must certify that products they purchase or otherwise acquire are used only for medically prescribed patient care and not for any penal purposes. Pfizer further requires that these Government purchasers certify that the product is for "own use" and will not resell or otherwise provide the restricted products to any other party.

In February of 2017 we amended Pfizer's Position on Use of Our Products in Lethal Injections for Capital Punishment to include four additional drugs that may be misused in lethal injection protocols: atracurium besylate, etomidate, potassium acetate and potassium phosphates.

We have twice communicated to the Departments of Correction in the 31 states permitting use of lethal injection for capital punishment that Pfizer strongly objects to the use of its products as lethal injections for capital punishment. We have asked all such states to return any Hospira or Pfizer manufactured Restricted Product in their possession and provided them with procedures to follow in return for a full refund.

Pfizer did not directly supply the product to the Arkansas Department of Correction (DOC). Without Pfizer's knowledge, McKesson, a distributor, sold the product to the DOC. This was in direct violation of our policy. Pfizer has twice requested that Arkansas return any Hospira or Pfizer manufactured Restricted Product in their possession. In addition, we considered other means by which to secure the return of the product, up to and including legal action.

After careful consideration, we determined that it was highly unlikely that any of these means would secure the timely return of the product and thereby prevent this misuse.

Pfizer's current policy is publically available at [http://www.pfizer.com/files/b2b/Global Policy Paper Lethal Injection 02.03.17.pdf](http://www.pfizer.com/files/b2b/Global_Policy_Paper_Lethal_Injection_02.03.17.pdf)

#